Loading briefing details...
Loading briefing details...
News Abstract
By: PointLine Media Research & Editorial Team
Topic:Business,Science & Environment
June 30, 2026
Ace Therapeutics has introduced an expanded suite of contract research services tailored for the development of pain management medications. The platform offers end-to-end support for pharmaceutical and biotechnology firms, spanning the entire lifecycle from early target identification to final safety testing.
The company provides a wide array of standardized in vivo models, including those for migraine and various forms of neuropathic pain. Researchers can utilize established testing methodologies—such as the Von Frey and Hot Plate tests—to generate data on mechanical, thermal, and chemical pain responses.
In addition to animal studies, the firm offers in vitro capabilities using specialized cell systems to investigate cellular pain mechanisms. The service pipeline covers small molecules, biologics, and cell-based therapies, supported by pharmacokinetic and toxicity assessments to streamline the candidate selection process.
The demand for more effective, non-addictive pain treatments remains a significant challenge for the global pharmaceutical industry. As regulatory requirements for preclinical data become increasingly stringent, companies are leaning on specialized research organizations to navigate the complexities of pain mechanism validation.
This shift toward outsourcing allows developers to access sophisticated, ready-to-use models, reducing the time and overhead associated with internal facility maintenance and specialized assay development.